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Abstract The ability to precisely regulate gene expression is
one of the most important features of the living cells as it
enables the adaptation and survival in different environmental
conditions. The majority of regulatory mechanisms involve
protein action, however, multiple genes are controlled by
nucleic acids. Among RNA-based regulators, the riboswitches
present a large group of specific domains within messenger
RNAs able to respond to small metabolites, tRNA, secondary
messengers, ions, vitamins or amino acids. A simple, accurate,
and efficient mechanism of action as well as easiness in han-
dling and engineeringmake the riboswitches a potent practical
tool in industry, medicine, pharmacy or environmental protec-
tion. Hereby, we summarize the current achievements and
challenges in designing and practical employment of the
riboswitch-based tools.
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Introduction
Regulation of gene expression includes a wide variety of
mechanisms used by cells to specifically increase or decrease
the expression of gene products (RNAs or proteins). Every
step of gene expression can be modulated, from transcription
initiation through the RNA processing and finally to the post-
translational protein modifications. Gene expression control at
the level of nucleic acids is largely prevalent and well known
in nature. Such mechanisms often include direct interactions
between DNA or RNA and proteins (e.g., transcription fac-
tors, activators or repressors). Many regulatory proteins act
simultaneously as molecular sensors, where formation of
ligand-protein complex allows for maintaining a strict control
over gene expression in response to various environmental
stimuli.
Some domains of mRNA also possess the ability to sense
small molecules and evoke regulatory effect. Such structures
are called riboswitches and are found in all three domains of
life. Riboswitches are regulatory, non-protein coding elements
within mRNA, able to directly bind small metabolites, un-
charged tRNA, secondary messengers, or ions. Bacterial
riboswitches of 17 different classes are discovered in 36 hu-
man bacterial pathogens that can be targeted for addressing
the ever-growing need for new antibiotics (Breaker 2012).
The size of riboswitches ranges from 34 nt for pre-queosine
riboswitch to approximately 200 nt for lysine riboswitch.
Riboswitches are especially common in Gram-positive bacte-
ria, where they control the expression of at least 4 % of genes
(Lünse et al. 2011). However, they are also found in eukary-
otes (Cheah et al. 2007) and most likely in archaea (Weinberg
et al. 2010).
Riboswitches are successfully competing with proteins for
high sensitivity and accuracy in gene expression regulation.
Therefore there is a reason to believe that the RNA World
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organisms could have used similar RNAs before the emer-
gence of enzymes and genetic factors made of protein. The
characteristics of some riboswitches strongly support this hy-
pothesis. Furthermore, some riboswitch ligands are proposed
to be molecular relics from an RNA World (Benner et al.
1989).
Riboswitches structure
Structurally, riboswitches are composed of two regions: (i)
evolutionary conserved aptamer domain, which is responsible
for ligand sensing (presented in red in Fig. 1) and (ii) variable
expression platform, controlling the gene expression (present-
ed in blue in Fig. 1). Genes controlled by the concentration of
a given metabolite are usually engaged in its biosynthesis,
metabolism or transport.
A plethora of ligands binding to riboswitches, each recog-
nized in accurate and specific manner requires a unique archi-
tecture perfectly matched to a given molecule. Additionally,
different riboswitches belonging to one class may regulate the
expression of more than one gene. For this reason,
riboswitches reveal a huge diversity of structures. On the other
hand, genes controlled by riboswitches are often involved in
crucial metabolic pathways and cellular processes, thus the
ligand-specific aptamer domains are usually strongly evolu-
tionary conserved.
Based on structural features, riboswitches can be divided
into two large groups: (i) pseudoknoted and (ii) junctional
riboswitches (Serganov and Nudler 2013). In the case of
pseudoknoted riboswitches, the RNA chain is predominantly
folded into a single knot-like structure, composed of two
stem-loops, where the part of one loop is engaged in base
paring with the second loop. Such structures are found, among
others, in pre-queosine, SAM-II and fluoride riboswitches
(Gilbert et al. 2008; Klein et al. 2009; Li and Breaker 2012;
Liberman et al. 2013). The ligand may interact with either the
junctional region between helices or along the groove of the
helix stabilized by pseudoknot.
The second group, the junctional riboswitches, is com-
posed of a central loop playing a role of multihelical junction
and several radial helices. The number of helices is variable
and ranges from three for purine and thiamine pyrophosphate
(TPP) riboswitches (Serganov et al. 2004, 2006) up to six for
flavin mononucleotide (FNM) riboswitch (reviewed in
Serganov and Patel 2009). The ligand binding site is usually
located within the junction or regions adjacent to it, however,
in some cases, the ligand may interact with distant regions of
the riboswitch.
Riboswitch-based regulatory mechanisms
Due to the architectural diversity, riboswitches can recognize a
wide range of biologically important substances (for detailed
review see: Peselis and Serganov 2014). The most abundant
group comprises coenzymes and related molecules like:
adenosylcobalamin (AdoCbl), thiamine pyrophosphate
(TPP), flavin mononucleotide (FMN), S-adenosylmethionine
(SAM), S-adenosylhomocysteine (SAH), tetrahydrofolate
(THF), and molybdenum/tungsten cofactors (Moco/Tuco).
The second largest group includes purines and their derivatives
such as: guanine, pre-queuosine-1 (preQ1), deoxyguanosine
(dG), cyclic-di-GMP (c-di-GMP), and cyclic-di-AMP (c-di-
AMP). Furthermore, three riboswitches response to the
presence of amino acids: lysine, glycine, and glutamine.
One specific riboswitch binds phosphorylated sugar,
glucosamine-6-phosphate (GlcN6P). The smallest ligands are
metal ions: Mg2+, F-, and recently discovered Ni2+/Co2+
(Furukawa et al. 2015) and Mn2+ (Price et al. 2015). Apart from
known and characterized riboswitches, there is also a group of so
called Borphan^ riboswitches-fully functional but without
reported ligand (Meyer et al. 2011).
Riboswitches employ a wide repertoire of regulatorymech-
anisms. They may either silence or activate the gene expres-
sion, operating at the level of transcription, translation, mRNA
degradation, splicing or RNA interference. The mechanism of
riboswitch action is based on the existence of two mutually
exclusive and thermodynamically stable conformations, sep-
arated by the energy barrier which inhibits the spontaneous
switching (Fig. 1). In general, when the concentration of rec-
ognized molecule reaches the binding threshold value, the
interaction with aptamer domain takes place. This promotes
the switching to the alternative fold by stabilization of the
intermediate and final states. The formation of riboswitch/
ligand complex results in structural changes in the expression
platform and consequently up- or down-regulation of gene
expression.
The most frequent riboswitch-based regulation comprises
transcription termination when in the presence of a ligand, the
termination hairpin is formed. Therefore, in most cases, if the
concentration of a ligand decreases in time, the anti-terminator
structure is being formed within the expression platform by
rearranging the conformation of one of the termination hairpin
arms into the alternative structure (Fig. 1, upper panel). In
such conformation, the mRNA expression is activated
(Gilbert et al. 2006).
A portion of the riboswitches is involved in rho-dependent
transcription termination. Rho factor is an essential transcrip-
tion protein in prokaryotes with helicase activity. Rho binds
synthesized RNA using its ATPase activity to provide the
energy to translocate along the RNA until it reaches the
RNA–DNA helical region, where it unwinds the hybrid du-
plex structure and prematurely terminates the transcription
(Gilbert et al. 2006). Such mechanism is used by
magnesium-sensing riboswitch in mgtA gene in Salmonella
enterica or FMN riboswitch upstream ribB gene in E. coli
(Hollands et al. 2012). In those cases, the presence of a
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respective ligand facilitates interactions with Rho helicases
and contributes to premature transcription termination.
The mechanism of riboswitch-based translation control is
primarily based on a similar system. However, the changes
within the expression platform are related to the modulation
of the ribosome binding site (RBS) accessibility instead of a
termination stem formation (Fig. 1, lower panel). SAM-II
riboswitch might serve as an example where the ribosome
binding site is sequestered by the aptamer domain in the pres-
ence of SAM (Haller et al. 2011). In contrast, adenine
riboswitch within the Add mRNA from Vibrio vulnificus is
able to induce the protein synthesis upon the ligand binding by
release of a Shine-Dalgarno sequence and a start codon
(Reining et al. 2013).
One of the most interesting mechanisms for riboswitch-
mediated gene control integrates ligand binding and ribozyme
activities. A ribozyme is a ribonucleic acid enzyme that cata-
lyzes a chemical reaction. Representatives of the glmS
riboswitch class function as metabolite-responsive self-cleav-
ing ribozymes, where GlcN6P serves as a cofactor for an
autocatalytic cleavage of GlmS mRNA (Cochrane et al.
2007). After the cleavage, the mRNA is devoid of phosphate
group at the 5’ end and therefore is susceptible to degradation
by cellular RNase J, resulting in a reduction of GlmS mRNA
level (Collins et al. 2007). An interesting example is the lysine
riboswitch located upstream of lysC gene from E. coli, which
presents a combined mechanism of gene expression regula-
tion. The lysine binding causes the translation inhibition by
modulation of the RBS accessibility. Simultaneously RNase E
cleavage site becomes exposed, which promotes the degrada-
tion of a transcript (Caron et al. 2012).
Catalytic riboswitches can also be involved in regulation of
RNA splicing. In bacteria, the known example is a c-di-GMP
riboswitch in Clostridium difficile, which is located adjacent
to the self-splicing intron in CD3246 mRNA, involved in
bacteria virulence (Chen et al. 2011). In a presence of a c-di-
GMP, a structural rearrangement promotes the choice of the
splice site, which results in production of functional mRNA
harboring the RBS. In contrast, when the concentration of c-
di-GMP is low, the alternative 5’ splice site is selected, which
subsequently leads to the exclusion of the RBS, thus
preventing the expression of the protein.
Although the regulation of gene expression by
riboswitches is generally a hallmark of prokaryotic organisms
(especially Gram-positive bacteria), one example, namely the
TPP riboswitch, was also found in eukaryotes. Usually, in the
case of bacteria, TPP riboswitch operates at the transcriptional
level (Bian et al. 2011). Eukaryotic TPP riboswitch controls
the splicing and the stability of transcript instead. As a conse-
quence, eukaryotic TTP riboswitches are located in introns or
3’UTRs of selected mRNAs (Cheah et al. 2007; Wachter et al.
2007). Introns may be excellent vehicles for riboswitch ex-
pression and regulatory function, and therefore may yield fu-
ture riboswitch discoveries.
Riboswitches as potential antimicrobial drug targets
The ability of the riboswitches to precisely discriminate be-
tween different cognate molecules as well as their common
existence in bacteria makes them a promising target for anti-
bacterial drug therapy (Fig. 2). From a medical point of view
this issue is crucial because of a continuously progressing
Fig. 1 General mechanism of riboswitch action. The change in the
structure of aptamer domain (red) triggered by metabolite binding (pink
diamond) is transferred to expression platform (blue) causing switch in
gene expression. The modulation of expression platform can cause the
formation of transcription termination hairpin (terminator, upper panel) or
differential accessibility of ribosome binding site (RBS, lower panel)
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problem of bacterial resistance against regular antibiotics. The
potential application of riboswitches as novel antimicrobial
drug targets has several important advantages over classic
antibiotics. First, they demonstrate potentially lower toxicity
due to the fact that riboswitches are not found in higher eu-
karyotes, including human. Additionally, a lot of them are
controlled by small compounds, simple metabolites, easy to
deliver into the system, but also to manufacture and modify.
The possibility of developing the resistance by bacteria
against the antibiotics targeted at riboswitches seems to be
more restricted than in the case of commercial drugs. The
presence of a single type of riboswitches in multiple bacterial
genes makes a single mutation insufficient to neutralize anti-
microbial effect.
To consider riboswitches in terms of a potential pharmaceu-
tical therapy, first of all, the analogs of ligands have to be found.
Next, the administration of such compounds should permanent-
ly induce riboswitches even in the absence of native ligands.
Purine riboswitches
A group of riboswitches potentially applicable in the medicine
are guanine, adenine, 2’-deoksyguanosine, and prequeuosine
(preQ1) riboswitches, collectively termed as purine
riboswitches. The genes controlled by these riboswitches are
usually engaged in transport and metabolism of purines and
may induce or silence gene expression after activation
(reviewed in Lünse et al. 2014). The aptamer domains of
guanine and adenine riboswitches are very similar and the
difference lies basically in one nucleotide, pyrimidine at the
74th position, able to formWatson-Crick interactions with the
ligand (Gilbert et al. 2009). After determining the exact
nucleotide, cytosine or uridine, the riboswitch recognizes gua-
nine or adenine, respectively and C>U transversion alters
specificity from G to A. The sequences flanking the 74th
nucleotide do not play any important role in ligand recognition
but are responsible for increasing specificity and affinity by
stabilization of purine in proper position (Mandal and Breaker
2004).
Because purines are essential for bacterial survival, a lot of
effort is made to discover suitable analogs. It has been proved
that some of the rationally designed analogs can bind the
riboswitch with comparable affinity as guanosine and some
additionally decrease bacterial growth (Kim et al. 2009). One
of such analogs, 6-N-hydroxylaminopurine, was observed to
repress the reporter gene expression downstream of the gua-
nine riboswitch, hence regulatory effect may be ascribed to
riboswitch activity.
Another potential riboswitch-targeting compound is 2,5,6-
triamino-pyrimidin-4-one (PC1) (Mulhbacher et al. 2010).
This compound was tested for its antibacterial properties on 15
strains of Gram-positive bacteria. In the case of nine strains, an
inhibition of growth was observed. In this group of bacteria,
guanine riboswitch controls guaA gene encoding GMP
syntetase, whereas the resistant strains employ a different mech-
anism of guaA regulation. Among PC1-responsive bacteria
there are found, inter alia , dangerous for human
Staphylococcus aureus and S. eidermidis. PC1 was also tested
on amurinemodel ofmastitis caused by S. aureus infection. The
results showed four order of magnitude decreases in the number
of viable bacterial cells after PC1 administration. Moreover, it
was observed that the presence of a reducing agent like DTT
improved the potency of the therapy, achieving antibacterial
activity comparable to those of some antibiotics. The drug was
Fig. 2 Mechanism of action of natural versus artificial antimicrobial
compounds targeting riboswitches. Left panel: In most of the cases
riboswitches are involved in the regulatory feedback loops by sensing the
concentration of the metabolite (pink diamond) produced or imported into
the cell by proteins under their control. When the concentration of the
compound is dropping due to use in cell metabolism, the protein
expression is activated (ON). After rise of the metabolite concentration,
expression is again suppressed (OFF). Right panel: The riboswitches are
targeted by artificial analogs of the original ligands (turquoise diamond). In
order to be effective, the analog should not be used as a substrate in cell
metabolism, causing permanent stalling of the riboswitch in the bound state.
In case of the perturbation of a typical feedback loop, such stalling will lead
to inhibition of the metabolite synthesis or uptake leading to cell death
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also examined on dairy cows (Ster et al. 2013). However, de-
spite the significant reduction of bacteria in milk, only 15 % of
subjects completely recovered, which can indicate the future
need of the optimization of the therapy.
Lysine riboswitch
The lysine riboswitch is usually situated upstream of lysC and
lysP genes. The first gene encodes for aspartokinase II respon-
sible for phosphorylation of aspartate in the initial step of
lysine, methionine, and threonine biosynthesis pathways.
The second gene encodes the lysine permease. The lysine
riboswitch is one of the largest (~200 nt in length) and most
complex (five stem-loops) riboswitches. The lysine is tightly
enveloped in a binding pocket enabling the discrimination by
the length of the amino acid as well as a terminal amine group
of the side chain (Sudarsan et al. 2003).
As a result of the screening for lysine analogs, four initially
promising antimicrobial compounds were selected: L-
aminoethylcysteine (AEC) (Ataide et al. 2007), L-3-[(2-
Aminoethyl)-sulfonyl]-alanine, L-4-oxalysine, and Dl-trans-2,
6-diamino-4-hexenoic acid (Blount et al. 2007). These com-
pounds have similar affinity to the aptamer domain in compar-
ison to lysine and they were shown to repress the gene expres-
sion by riboswitch activation. The last three analogs showed
about fivefold decrease in bacteria concentration after 6 hours
of incubation in comparison to untreated culture. Additionally
they were able to completely inhibit bacterial growth for nearly
24 hours. However, some studies showed that AEC might be
incorporated into proteins in mammalian and bacterial cells,
which might lead to their toxicity (Di Girolamo et al. 1986,
1990). Furthermore, there areAEC-resistant bacteria strainswith
accumulated mutations in lysine riboswitch aptamer domain.
Apart from the lysine riboswitch, AEC binds as a primary target
to the lysil-tRNA-synthetase (LysRS) in bacteria (Ataide et al.
2007). It explains the observation of elevated level of free, cel-
lular lysine in the case of down regulated lysC gene, since AEC
competes with lysine for binding LysRS. The existence of addi-
tional target for lysine analog, independent of the site where the
resistance can emerge, indicates future direction of more prom-
ising drugs, designed to effectively bind both lysine riboswitch
as well as bacterial LysRS.
Cyclic-di-GMP riboswitch
Cyclic-di-GMP is a major prokaryote signaling secondary
messenger. Considering eukaryotic organisms, its presence
has been reported only in one species of amoebas
(Dictyostelium discoideum, Chen and Schaap 2012), which
makes c-di-GMP a perfect candidate for an antibiotic in the
context of human safety. This compound controls a variety of
different functions like: virulence, adhesion, cell aggregation,
and biofilm formation. The most tempting for researchers is
the possibility to control the bacterial virulence via modula-
tion of c-di-GMP metabolism.
There are two classes of c-di-GMP riboswitches. Class I
employs a classical mechanism of translation or transcription
termination of downstream genes (Sudarsan et al. 2008). In
contrast, class II c-di-GMP riboswitches functions as
allosteric self-splicing ribozymes. In this case binding of the
ligand promote the formation of the splicing product contain-
ing functional SD sequence in vicinity of the start codon,
leading to activation of gene expression (Lee et al. 2010).
The level of ligand discrimination by class II riboswitches is
lower in comparison to class I (Shanahan et al. 2011). For both
classes, the ribose with 3’-endo conformation is important as it
provides high affinity ligand binding.
An example of effectively binding analog of c-di-GMP is
endo-S-c-di-GMP (Zhou et al. 2012). This analog shows sta-
ble cyclic conformation which is crucial for the recognition by
riboswitch. However, due to the fact that it is characterized by
fourfold lower affinity compared to the natural ligand, further
functional studies or optimization have to be performed.
Another promising group of compounds which might mimic
cyclic forms of di-GMP are their linear forms (Furukawa et al.
2012). As recently demonstrated in β-galactosidase expression
assay, some of them are characterized by high affinity binding
and strong induction of the riboswitch. However, on closer in-
spection, some ligand-unresponsive mutants also showed similar
expression profiles, which suggests that the therapeutic effect of
linear di-GMPcannot be attributed to the riboswitch activity only.
glmS riboswitch
The glmS gene is present in many groups of Gram-positive bac-
teria since it encodes the protein converting fructose 6-phosphate
phosphate and glutamine to glucosamine-6-phosphate (GlcN6P).
The resulting aminosugar plays a crucial role in bacterial cell wall
biosynthesis (GlcN6P is a precursor of peptydoglycan), being
simultaneously indispensable for bacteria viability. 5’UTRof this
gene operates as both ribozyme and riboswitch, catalyzing its
own excision, leading to degradation of mRNA by RNase J1
(Collins et al. 2007). The glmS riboswitch is predicted to exist
in at least 18 Gram-positive organisms, therefore it would be
desirable to provide compounds that target this riboswitch and
exhibit antimicrobial activity.
In order to define crucial structural features and functional
groups necessary for the recognition by glmS riboswitch, the
library of potentially active substances has been constructed.
Upon library screening, it has been noticed that the amine
group is important for enzymatic activity of the riboswitch
and phosphate group is essential for high affinity ligand bind-
ing (Winkler et al. 2004; McCown et al. 2011). High level of
molecule discrimination posed a challenge for researchers to
identify the functional analog able to specifically block the
riboswitch in its bound state.
J Appl Genetics (2016) 57:531–541 535
The final breakthrough has been made in 2007 when carba-
GlcN6P was proposed as a potential medicine for
Staphylococcus auresus infections treatment and this compound
is a subject of pending patent application (U.S. Patent No.
20140066409 A1, 2014). Finding a potent drug able to cure
S. aureus infection is of special importance given the fact that
this bacterium is an example of multiresistant strain. In the case
of carba-GlcN6P, it has been noticed that both, the capability of
the substrate cleavage as well as the reaction rate constant was
performed with similar efficiency compared to the native ligand.
Also bacterial growth was reduced by threefold in comparison
to the control culture and a twofold decrease in glmS gene ex-
pression level was observed (Lünse et al. 2011).
TPP riboswitch
Thiamine pyrophosphate (TPP) is a derivative of vitamin B1,
thiamine, an important cofactor of many enzymes involved in
sugar and amino acid metabolism. In the cytoplasm, thiamine is
metabolized to TPP by enzyme thiamine pyrophosphatase which
makes this molecule biologically active (Ontiveros-Palacios et al.
2008). TPP riboswitches are located upstream of the genes en-
gaged in transport and biosynthesis of TPP. Binding of the ligand
causes the genes repression, mainly by transcription attenuation.
The recognition of the ligand occurs within two helices: one
interacts with pyrophosphate; the second recognizes pyrimidine
of TPP (Thore et al. 2006).
The first described TPP analog demonstrating antibacterial
properties, was pyrithiamine (PT) (Sudarsan et al. 2005). It
was shown that both extrinsic and intrinsic PT inhibits bacte-
rial growth and this toxic effect was fulfilled via down-
regulation of genes under control of a TPP riboswitch. The
same studies also revealed a mechanism of resistance acqui-
sition during the evolution by accumulation of point mutation,
usually A to G, in aptamer domain to disrupt PTPP-riboswitch
binding. In the case of B. subtilis, such mutations occur in the
riboswitch upstream of the tenA operon which functions as
thiaminase. Interestingly, tenA by breaking PTPP into two
molecules enhances the resistance effect.
Apart from the PT there is a growing number of a wide
spectrum of TPP analogs with a sufficient binding, like:
oxythiamine (Thore et al. 2008), amprolium, 4-methyl-5-
hydroxyethylthiazole (Winkler et al. 2002a, 2002b) or
benfothiamine (Edwards and Ferre-D’Amare 2006).
However, these compounds did not seem to be as effective
as PT in the activation of the TPP riboswitch.
FMN riboswitch
FMN riboswitch controls the genes engaged in transport and
biosynthesis of vitamin B2—riboflavin. In the cell, riboflavin
is converted to FMN by riboflavin kinase and then to flavin
adenine dinucleotide (FAD) by FAD synthetase. Both
substances constitute essential coenzymes in multiple oxidation
and reduction reactions, and play a central role in energy metab-
olism (fats, sugars, carbohydrates, and proteins). The recogni-
tion of FMN occurs in a binding pocket composed of two pe-
ripheral stem-loops by interaction via a phosphate moiety, flavin
ring, the ribityl with the aptamer domain in riboswitch (reviewed
in Serganov and Patel 2009). The binding entails structural re-
arrangements leading to sequestration of SD sequence, and con-
sequently, repression of a given gene (Ott et al. 2009).
The analog of riboflavin produced by Streptomyces
davawensis—roseoflavin—is the only known example of natu-
rally existing antibiotic targeting the riboswitch (Lee et al. 2009;
Ott et al. 2009). Roseoflavin, after its biosynthesis, is excreted to
the environment inducing antibacterial effect in bacteria species
containing FMN riboswitch, which as a consequence helps to
gain an advantage in struggle for survival. In the cells,
roseoflavin is converted to roseoflavin-5-monophosphate
(RoFMN) and interacts with the FMN riboswitch. This ligand
is characterized by higher binding affinity in comparison to
native FMN but the pattern of recognition remains similar. The
research conducted on resistant and sensitive strains showed that
single nucleotide at position 61 in the aptamer plays a crucial
role in ligand discrimination (Pedrolli et al. 2012).
Riboswitch-based gene expression control systems
The conditional control of gene expression has been the focus of
attention of scientists for years. Although several systems of
gene expression regulation exist, the riboswitch-based system
is still able to contribute new quality to this field. It is character-
ized by several interesting features. First of all, riboswitches are
often activated by small and simple compounds reducing costs
of exploitation of such a system, even in industrial scale (for
example IPTG is a much more expensive inducer of lacZ sys-
tem). Furthermore, most of the ligands are small enough to
penetrate a bacterial cell wall and cell membrane, which means
that administration to the medium is sufficient to evoke regula-
tory effects. It appears to be an advantage in comparison, for
instance, to antisense strategy where the antisense oligonucleo-
tides have to be administered to the cells in suitable vectors like
liposomes. Variety of different riboswitches makes them a flex-
ible tool to control a broad repertoire of different genes. They
utilize a diverse spectrum of regulatory mechanisms, from tran-
scription termination to splicing control. Moreover, ligand bind-
ing may induce both down- or up-regulation, depending on the
context in which aptamer domain is placed, increasing flexibility
and potential range of application.
Riboswitch-based control of Mycobacteria gene expression
Inducible gene expression systems are widely exploited to ana-
lyze the gene essentiality (reviewed in Judson and Mekalanos
2000), function and potential drug targets (Miesel et al. 2003;
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Payne et al. 2007). There are several systems for gene expression
control, however, most of them are limited to Gram-negative
bacteria or related species. The example of such bacteria, impor-
tant from the medical point of view are mycobacteria, including
Mycobacterium tuberculosis (Mtb) and related species function-
ing as a model of tuberculosis, like fish pathogen M. marinum,
non-pathogenic M. smegmatis, and bovine strain M. bovis used
for BCG vaccines. All those species are important for health care
and hard to handle for molecular genetics due to slow growth
rate and risk of infection (reviewed in van Kessel et al. 2008).
There are regulatory systems available for mycobacteria, namely
acetamide-inducible Msmeg acetamidase promoter (Brown and
Parish 2006) or tetracycline repressor-based system (Ehrt et al.
2005). However, both of them require suitable proteins to elicit
regulatory effect which makes the whole system complex, diffi-
cult to calibrate and precisely control.
In 2012 the artificial theophylline-responding riboswitch was
constructed to control gene expression in a wide spectrum of
Gram-negative and Gram-positive bacteria, including
M. smegmatis, a model for studies on tuberculosis (Seeliger
et al. 2012). The theophylline riboswitch-based system consists
of a synthetic aptamer domain sensing theophylline and a my-
cobacterial promoter of total length of about 300 nt. This system
was used to induce and repress heterologous protein overexpres-
sion reversibly, to create a conditional gene knockdown, and to
control gene expression in a macrophage infection model. In the
absence of theophylline, the riboswitch adopts closed conforma-
tion making RBS and start codon inaccessible for translation
machinery. Binding of theophylline induces structural alter-
ations of the riboswitch and translation can occur. In
M. smegmatis, the riboswitch construct demonstrated the activa-
tion ratio of ~89 for β-galactosidase and ~65 for GFP expres-
sion. The activation operated in a dose-dependent manner.
Similar results were obtained for M. tuberculosis though this
species is supposed to be even more sensitive to theophylline.
The fact which seems to be of great importance is that unlike
existing systems for controlling gene expression in Mtb, the
riboswitch does not require the co-expression of any accessory
proteins: all of the regulatory machinery is encoded by a short
DNA segment directly upstream of the target gene. Additionally,
the potential application of the theophylline-responsive
riboswitch system to animal models of infection would be facil-
itated by the fact that theophylline is an FDA-approved drug and
well tolerated in mice and guinea pigs.
Riboswitch-based control of virus gene expression
and replication
The discovery that some naturally occurring viruses have an
intrinsic preference to lyse cancer cells leads to the concept of
providing Boncolytic viruses^, that are viruses that preferentially
infect and kill cancer cells (Kelly and Russell 2007). The discov-
ery initiated numerous attempts to artificially improve oncolytic
properties by engineering known viruses (Wong et al. 2010).
Hence the focus on riboswitch-based expression control systems
capable of induction of viral genes in a reversible way.
Recently, two genetically modified viruses have been
engineered: adenovirus (AdVs) and measles virus (ssRNA
virus) with riboswitch-controlled gene expression (Ketzer
et al. 2014). The basic idea of such a strategy was that the
control of transgene expression by replication-deficient AdVs
and replication-competent OAds were achieved by insertion
of an aptazyme, a synthetic ligand-dependent self-cleaving
ribozyme, into the 5′- and/or 3′-UTR of the transcription unit.
Upon productive infection of a host cell with adenoviruses,
the viral genome is transcribed in the host nucleus, mRNA is
translated in the cytoplasm, and virions self-assemble in the
nucleus. With engineered adenoviruses the viral genome rep-
lication occurs only for replication-competent OAds in tumor
cells. Then, the transgenes are transcribed in the host nucleus.
The applied OFF switch, given by an aptazyme, allows for
transgene expression in the absence of ligand (gene expres-
sion ON). Upon addition of the ligand (theophylline), the
aptazymes can fold into an active conformation and mRNA
self-cleavage occurs (gene expression OFF). The studies
showed the effective shutdown of E14 gene expression ac-
companied with approximately 200-fold reduced replication
rate, triggered by the addition of theophylline into the medi-
um. This effect has been demonstrated in several cell lines.
Positive results were also achieved for measles virus (Ketzer
et al. 2014). Here, the same aptazymes were incorporated in 5’
and 3’ UTRs of F gene encoding the F protein responsible for
fusion of the host and viral cell membrane after attachment of
the virus particle, controlling viral entry into the cell and spread-
ing. The experiment proved that addition of theophylline re-
duced viral particles progeny up to 50-fold after 48 h.
In conclusion, because of their small size and RNA-intrinsic
activity, the aptazymes could be considered as an alternative for
inducible promoters in eukaryotic gene expression control.
Riboswitch-based gene expression in cell-like systems
The complexity of eukaryotic expression systems often makes
certain phenomena hard to be fully understood. Therefore, an
interesting alternative could be artificial cell-like systems that
mimic key features of life with defined components but sim-
plified and much easier to operate and regulate.
In 2011 Martini and Mansy presented an example of exter-
nally stimulated RNA-controlled function in two artificial cell-
like systems: vesicle and water-in-oil emulsions (Martini and
Mansy 2011). They have used previously selected theophylline
riboswitch and constructed a working system with the use of
yellow fluorescent protein DNA as a genome with T7 promoter
and E. coli RBS. As a result, upon riboswitch activation by the
ligand, the RBS was exposed for translation apparatus. The
production of a reporter protein was active only in the presence
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of theophylline. Such a clear demonstration of controlled gene
expression in water droplets and vesicles adds experimental
verification to the ongoing origin of life research looking at
compartmentalization of functional units.
Riboswitches as riboselectors
Riboswitches could be considered as sensor-actuator hybrids
that can control gene expression in response to intracellular
metabolite concentration. These characteristics substantiate
the need for development of a riboswitch-based selection de-
vices in order to expedite the evolution of metabolite-producing
microorganisms. This device was named Briboselector^ and its
function was to specifically sense inconspicuous metabolites
(Yang et al. 2013). A riboselector is comprised of two mod-
ules: a riboswitch and a selection module. Riboselectors can
therefore efficiently optimize metabolic pathways by linking
the intracellular concentration of a particular metabolite to
survival of the cell under selection pressure. The lysine
riboselector used by Yang et al. consisted of a lysine
riboswitch from lysC of E. coli and the selection marker
tetA. lysC gene encodes lysine synthase, which after lysine
binding reduces downstream gene expression (Jang et al.
2015). A selective marker—tetA—encodes a tetracycline/
H+ antiporter. Dual-selection modes of TetA enabled cells
that accumulate lysine in the cytoplasm to survive in the
presence of toxic metal salts, such as NiCl2. The application
of positive selection pressure (addition of NiCl2) enriched
the bacterial culture in higher lysine producer. Bacterial
clones producing the largest amounts of lysine were able
to repress tetA gene expression efficiently, thus could survive
and replicate. In this system, a 75 % increase of a lysine
production level was achieved after four cycles of the selec-
tion process. As a conclusion, riboselectors can give a
growth advantage to metabolite-overproducing strains by
modulating the expression of a selectable marker gene.
Riboswitches as biosensors
A biosensor is an analytical device, used for the detection of
an analyte that combines a biological component with a phys-
icochemical detector. There is a wide variety of biological
compounds used as recognition elements, including enzymes,
antibodies, receptors, RNA, DNA, organelles, tissues, and fi-
nally whole cells (Han et al. 2010; Arora 2013). Recognition
of a given molecule usually triggers a release of electrochem-
ical or optical signal collected and quantified by the detector
(Arora 2013). The most commonly used type of biosensor is
an enzymatic one; nevertheless, the production of a high
amount of enzymes is expensive and requires meticulous pu-
rification (Su et al. 2011). Hence, the scientific efforts were
focused on immobilized whole-cell biosensors as they are
characterized by low cost and improved stability in compari-
son to enzyme-based biosensors (Park et al. 2013).
Riboswitches offer a new promising approach to the bio-
sensor field. The sensing ability of riboswitches (that is the
sequence of the aptamer domain) might be generated de novo
according to the needs by an in vitro selection process known
as Systematic Evolution of Ligands by EXponential
Enrichment (SELEX). This experimental procedure allows
us to obtain the aptamer domain of a riboswitch responding
to almost any small compound. Such artificial riboswitches,
similarly to natural ones, bind ligands even in very low con-
centrations in a dose-dependent manner (Fig. 3).
In 2009, an anti-asthmatic drug theophylline biosensor was
developed (Jo and Shin 2009). Monitoring of theophylline con-
centration in the blood is of special importance since its overdose
can be dangerous for health causing seizures and heart rhythm
disturbances (Pernites et al. 2011). The created biosensor was
composed of a theophylline binding aptamer domain (serving as
a sensing element) linked to the 5’ end of GFP coding sequence.
The interaction of theophylline with the riboswitch caused a
dose-dependent induction of GFP expression detected and trans-
lated to quantitative digital data by the signal transducer.
Fig. 3 Employment of riboswitches as biosensors. The most common is
the fusion of the specific artificial aptamer domain selected for a binding
of a compound of interest (purple diamond) with the expression platform
and a coding sequence of GFP protein. Such construct is
introduced into bacterial cells. Due to the concentration-specific action
of riboswitches, the transformed cells produce different amounts of GFP
depending on the compound concentration within the cell (left vs right
panel). Thus, the concentration of a compound could be estimated via
GFP fluorescence measurement of the bacterial culture
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Riboswitch-based control of bacterial behavior
Achievements of modern bioengineering in the field of micro-
biology allow us to control not only bacterial gene expression
but also cell behavior, especially in terms of cell motility.
Bacteria are naturally adapted to sense and respond to chemical
signals from the surrounding environment. The basis of the
bacteria chemical responsiveness is chemotaxis, the ability to
recede or follow a given molecule according to its gradient in
the habitat. Usually, a given chemical compound is recognized
and bound by the surface receptor which causes the activation of
the cascade of cytosolic proteins able to control flagellar motor
complex (reviewed in Baker et al. 2006). It allows bacteria to
avoid harmful substances and occupy habitats rich in nutrients.
Generally, the possibility to regulate bacterial mobility would
be beneficial in a variety of different fields, like environmental
protection to enhance bioremediation, targeted therapy or in
performing complex tasks which require cooperation of more
than one bacteria strain. In 2007 Topp and Gullivan showed that
the E. coli chemotaxis system could be reprogrammed by plac-
ing a key chemotaxis signaling protein cheZ under the control of
a theophylline-sensitive riboswitch (Topp and Gallivan 2007).
Reprogrammed cells migrated up gradients of this ligand and
autonomously localized to regions of high theophylline concen-
tration, which is a behavior that cannot be accomplished by the
natural E. coli chemotaxis system.
Conclusions
Discovery of the riboswitches more than ten years ago
gave scientists completely new possibilities of gene ex-
pression control within the cells (Table 1). Just as natural
riboswitches can regulate gene expression in response to
small-molecule ligands during transcription or translation,
synthetic riboswitches can be engineered to repress or ac-
tivate gene expression in a ligand-dependent fashion.
Several interesting ideas have appeared so far to explore
naturally existing or artificial riboswitches. The develop-
ment of different analogs of native ligands finds potential-
ly broad application in the field of medicine. Substances
targeting riboswitches which control crucial bacterial genes
might therefore constitute a novel potential source of an-
timicrobial drugs. The examples discussed herein reveal
that increasing attention has been drawn to riboswitches
and a number of intriguing compounds are available to
date. Some of them have proven to be active in in vitro
bacterial growth assays, but only one, targeting the gua-
nine riboswitch of S. aureus, has been taken into animal
studies so far. Up to date practical use of such compounds
is limited by two major factors: (i) it is hard to create a
compound which would retain the binding affinity of the
natural ligand and would not be incorporated into host
metabolic pathways and (ii) in most of known cases, the
antimicrobial effect of the riboswitch targeting is caused
by down regulation of a single gene or operon by a single
riboswitch, enabling a relatively fast acquisition of resis-
tance by bacteria.
On the other hand, possible modifications of riboswitch
sequences and fusion of different aptamers with genes of in-
terests pave a completely new way for generation of inducible
expression systems and biosensors. It seems that in this field
the major limitations have been overcome. Currently, there are
efficient SELEX-based protocols available for development
of aptamers specific for a wide range of molecules.
Therefore, synthetic riboswitches can be employed to regulate
the expression of any gene in response to any non-toxic mol-
ecule that is capable of being bound by RNA. This feature
should enable RNA switches to play an increasingly important
role as chemical biologists seek to modulate many types of
cellular behavior in response to a broad range of chemical
signals. What is more, apatmers used as conditional gene ex-
pression regulators or biosensors seem to provide both effi-
ciency as well as robustness.
Table 1 Summary of potentially applicable riboswitches
Ligand Gene Potential application Reference
Lysine lysC Antibacterial drug target Blount et al. 2007
Lysine lysC Riboselector Yang et al. 2013
Glucosamine-6-phosphate glmS Antibacterial drug target Lünse et al. 2014
Purines guaA Antibacterial drug target Mulhbacher et al. 2010
Flavin mononucleotide ribB Antibacterial drug target Pedrolli et al. 2012
Thiamine pyrophosphate tenA Antibacterial drug target Sudarsan et al. 2005
Theophylline - Gene expression control Seeliger et al. 2012
Theophylline E1A Virus gene expression and replication control Ketzer et al. 2014
Theophylline - Gene expression in cell-like system Martini and Mansy 2011
Theophylline CheZ Control of bacterial cell behavior Topp and Gallivan 2007
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The ideas of practical riboswitch application presented in
this article certainly do not exhaust the whole spectrum of
possibilities. A number of further applications await their dis-
covery, for development and implementation into practice.
Nevertheless, the future of riboswitches as a molecular tool
or antibacterial drug target seems to be genuinely promising.
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